Painreform (NASDAQ:PRFX) is committed to the development of innovative pain management solutions, with a focus on addressing post-operative pain through extended release drug applications. Currently, the company's projects include the formulation of drugs designed to provide prolonged pain relief, potentially reducing the need for opioids and improving patient outcomes after surgery. Painreform aims to revolutionize post-operative care by advancing these products through clinical trials and eventually bringing them to market for the benefit of patients worldwide. Their objective is not only to alleviate pain effectively but also to contribute to the fight against the opioid crisis by offering safer, non-addictive pain management alternatives.